Calling all Minocycline Users

duncan1 · Posted: Sun May 18, 2008 1:28 pm Post subject:

I may have been wrong about a German study in humans, but I could have sworn I read about a small scale, long term, trial of Minocyline at a USA university outpatient clinic, that produced excellent results.
I wasn't surprised at the Minocycline-ALS results as the small scale trials and individual case reports seemed to indicate that minocycline would have mixed results. There are also some concerns over dosage in the large scale ALS trial.

I have not heard about a single case report of Minocycline causing a more rapid onset of MS symptoms in humans, despite the thousands of MS patients who have been on tetracycline class antibiotics to treat acne/rosacea. MS and ALS have very different mechanisms of disease causation and the disease are not comparable, so linking ALS/minocycline failure with MS, was just scare mongering, IMHO. (Of course,I am referring to the Drs who made this statement, not anyone here...)

However, even in ALS, there are undoubtedly cases where the neurodegeneration is being caused by a underlying (probably) spirochetal infection, and the patient, if given antibiotic therapy, has a chance to recover. The problem, of course, is deciding which ALS patients should be treated with antibiotics, and which should not.

cheerleader · Posted: Mon May 19, 2008 8:24 am Post subject:

Hey Duncan-

My husband and I became interested in the antibiotic therapy years ago, before his MS diagnosis. We are fans and appreciators of pianist/composer Keith Jarrett, and watched his recovery from chronic fatigue and cpn infection with the antibiotic protocol. We saw him play live in LA after years away from the concert stage. It was extraordinary! The next year my husband was dx with MS, and suffered crippling fatigue. The connection was made...and I found this board. I believe there are no "coincidences."

That said, I also believe in having a good relationship with a doc when following any medical protocol. There is still too much we "laymen" do not understand about the human immune system (which is far more complex than a mouse's) The failure of mino in ALS was huge and disappointing to many suffering with this horrific disease, and also gave docs pause. This is the reason I advocate medical supervision and a bit o' caution.
best,
AC
_________________
Husband diagnosed RRMS March 2007
pursuing endothelial healing
Copaxone, Swank, supplements, laughter

MacKintosh · Posted: Sat May 24, 2008 11:05 pm Post subject:

Duncan, There is also the question of whether monotherapy with minocycline (or any abx, for that matter) is enough, or if an antibiotic cocktail is what will make all the difference in recovery versus decline.
_________________
The difference between what we do and what we are capable of doing would suffice to solve most of the world’s problems. Mohandas Gandhi

Cojack · Family Member Joined: Nov 12, 2008 Posts: 29

Hello Cheerleader, Oedipuss et al.....

any updates on how minocycline is working for jeff? i'm considering taking it.

thanks,

jack

duncan1 · Posted: Fri Nov 14, 2008 4:09 pm Post subject:

This is the abstract for a recent article regarding MS and Minocycline:

Can J Neurol Sci. 2008 May;35(2):185-91.

Pilot study of minocycline in relapsing-remitting multiple sclerosis.
Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, Mitchell JR.

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

BACKGROUND: Current multiple sclerosis (MS) treatment is only partially effective and not all patients respond well. The goal in this study was to evaluate minocycline for its safety, tolerability, and MRI impact as a potential therapy over 36 months after a three month run-in in ten relapsing-remitting (RR) MS patients. METHODS: Clinical assessments were at three month intervals until six months, then at six month intervals. Three Tesla MRI was performed monthly during the run-in and first six months of treatment, then at 12, 24, and 36 months. RESULTS: Treatment was safe and well tolerated. Annualized relapse rate was 1.2 during the run-in and 0.25 during treatment. The proportion of active scans was lower during the first six months of treatment (5.6%, p < 0.001) and during the extension (8.7%, p = 0.002) than during the run-in (47.5%). Consistent with these outcomes, mean T2 lesion volume remained stable over three years and percent brain volume change was reduced during year three (-0.37%) of minocycline treatment. CONCLUSIONS: This trial is limited by small sample and no control group but suggests that minocycline is safe and potentially beneficial in RRMS. This supports further investigation of its efficacy.
--------------------------

The U of Calgary is now conducting a large scale trial of about 400 people, IIRC.